BRIEF published on 07/17/2026 at 00:05, 3 months 27 days ago LIR Life Sciences Partners with Oxygen Handel for Regulatory Roadmap Obesity Treatment Transdermal Delivery Development Agreement GLP-1 Therapeutics Regulatory Roadmap
BRIEF published on 07/17/2026 at 00:05, 3 months 27 days ago LIR Life Sciences s'associe à Oxygen Handel pour une feuille de route réglementaire Traitement De L'obésité Administration Transdermique Accord De Développement Thérapeutiques GLP-1 Feuille De Route Réglementaire
BRIEF published on 07/16/2026 at 23:15, 3 months 27 days ago Marinomed Biotech AG Seeks Court-Approved Restructuring Amid Financial Strains Marinomed Biotech AG Financial Stability Insolvency Risk Unither Pharmaceuticals Court Restructuring
BRIEF published on 07/16/2026 at 23:15, 3 months 27 days ago Marinomed Biotech AG demande une restructuration approuvée par le tribunal en raison de difficultés financières Marinomed Biotech AG Stabilité Financière Risque D'insolvabilité Unither Pharmaceuticals Restructuration Du Système Judiciaire
BRIEF published on 07/16/2026 at 22:15, 3 months 28 days ago DBV Technologies publie son Rapport Financier Semestriel 2026 Rapport Financier Cotation Boursière DBV Technologies Allergies Alimentaires Technologie VIASKIN
BRIEF published on 07/16/2026 at 22:15, 3 months 28 days ago DBV Technologies Files 2026 Half-Year Report with AMF Half-year Report AMF Filing DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 07/16/2026 at 22:15, 3 months 28 days ago DBV Technologies publishes its 2026 Half-Year Financial Report Financial Report Stock Market Listing DBV Technologies Food Allergies Viaskin Technology
BRIEF published on 07/16/2026 at 22:15, 3 months 28 days ago DBV Technologies dépose son rapport semestriel 2026 auprès d'AMF. Allergies Alimentaires Rapport Semestriel Dépôt AMF Technologies DBV Patch VIASKIN
BRIEF published on 07/16/2026 at 22:06, 3 months 28 days ago DBV Technologies annonce ses résultats financiers et avancées cliniques pour le premier semestre 2026 Résultats Financiers FDA DBV Technologies Allergies Alimentaires Viaskin® Peanut
BRIEF published on 07/16/2026 at 22:06, 3 months 28 days ago DBV Technologies announces its financial results and clinical progress for the first half of 2026 FDA Financial Results DBV Technologies Food Allergies Viaskin® Peanut
Published on 11/13/2026 at 23:00, 14 minutes ago Grid Metals Announces Filing of NI 43-101 Mineral Resource Estimate Technical Report for the Falcon West Project
Published on 11/13/2026 at 22:30, 44 minutes ago Churchill Resources Announces Change in Chief Financial Officer
Published on 11/13/2026 at 20:15, 2 hours 59 minutes ago U.S. Export-Import Bank Features NioCorp's Elk Creek Critical Minerals Project in EXIM's Factory Floor Fridays Initiative
Published on 11/13/2026 at 18:30, 4 hours 44 minutes ago Sparta Capital Ltd. Announces Application to the Ontario Securities Commission to Become a Reporting Issuer in Ontario
Published on 11/13/2026 at 21:52, 1 hour 21 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 4 hours 5 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 4 hours 14 minutes ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 18:04, 5 hours 9 minutes ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 11 hours 39 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 11 hours 39 minutes ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 15 hours 14 minutes ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 1 day ago Belgrano continues the implementation of its public share buyback offer (OPRA)
